41.51
Precedente Chiudi:
$42.41
Aprire:
$42.77
Volume 24 ore:
486.68K
Relative Volume:
1.40
Capitalizzazione di mercato:
$2.87B
Reddito:
$751.00K
Utile/perdita netta:
$-74.57M
Rapporto P/E:
-37.63
EPS:
-1.1031
Flusso di cassa netto:
$-55.52M
1 W Prestazione:
+10.02%
1M Prestazione:
+57.89%
6M Prestazione:
+73.54%
1 anno Prestazione:
+182.19%
Pulse Biosciences Inc Stock (PLSE) Company Profile
Nome
Pulse Biosciences Inc
Settore
Industria
Telefono
510-906-4600
Indirizzo
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
PLSE
Pulse Biosciences Inc
|
41.51 | 2.27B | 751.00K | -74.57M | -55.52M | -1.1031 |
|
ISRG
Intuitive Surgical Inc
|
393.38 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
179.63 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
73.63 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
RMD
Resmed Inc
|
220.05 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
|
MDLN
Medline Inc
|
33.81 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | Mizuho | Outperform |
| 2025-07-07 | Iniziato | Oppenheimer | Outperform |
| 2021-07-27 | Iniziato | Stephens | Overweight |
| 2021-03-11 | Iniziato | Maxim Group | Buy |
| 2021-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-12 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Pulse Biosciences Inc Borsa (PLSE) Ultime notizie
Oppenheimer Adjusts Pulse Biosciences PT to $35 From $30, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises Pulse Biosciences stock price target on AF data - Investing.com
Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulse Biosciences Inc (PLSE) Cash Flow - TradingKey
PLSE|Pulse Biosciences Inc|Price:30.230|Chg%:-0.770 - TradingKey
TradingKey - TradingKey
Pulse Biosciences, Inc Revenue Breakdown – NASDAQ:PLSE - TradingView
This Little-Known Biotech Stock Just Hit a New 5-Year High - Yahoo Finance
Pulse Biosciences Inc (PLSE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulse Biosciences stock hits 52-week high at 31.09 USD By Investing.com - Investing.com Australia
Pulse Biosciences stock hits 52-week high at 31.09 USD - Investing.com
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026 - Finviz
Pulse Biosciences to report Q2 2026 results on August 6 - scanx.trade
$Pulse Biosciences (PLSE.US)$ squeeze baby squeeze - Moomoo
Pulse Biosciences, Inc (PLSE) Stock Analysis: Unpacking The 5.89% Potential Upside - DirectorsTalk Interviews
PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) - Moomoo
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Liquidity Mapping Around (PLSE) Price Events - Stock Traders Daily
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - AOL.com
Pulse Biosciences stock stays tied to filings and financing - AD HOC NEWS
Why (PLSE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Did Warrant Redemptions Just Reframe Pulse Biosciences' (PLSE) Cardiac Ablation Investment Narrative? - Sahm
Price to earnings forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
PLSE Forecast — Price Target — Prediction for 2027 - TradingView
Pulse Biosciences Shares Tumble Over 5% as Bearish Momentum BuildsMonthly Profile - dars.gov.et
Price to sales forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to EBITDA forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to EBIT forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to sales forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to earnings forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse Biosciences Inc (PLSE) Institutional Confidence - TradingKey
Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com - Investing.com Nigeria
Pulse Biosciences stock hits 52-week high at $28.68 - Investing.com
Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (FWB:6L8) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8) - TradingView
6L8 Forecast — Price Target — Prediction for 2027 - TradingView
Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth - Moomoo
Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting? - simplywall.st
Pulse Biosciences, Inc.(NasdaqCM:PLSE) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
Understanding Momentum Shifts in (PLSE) - Stock Traders Daily
Pulse Biosciences Stockweekly review and sector comparison - AD HOC NEWS
Pulse Biosciences Inc (PLSE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulse Biosciences Strengthens Executive Team - Medical Product Outsourcing
Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulse Biosciences Inc Azioni (PLSE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pulse Biosciences Inc Azioni (PLSE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):